TRIAL DATA
Aflibercept plus 5-FU shows promise for frail elderly patients with metastatic colorectal cancer — European Journal of Cancer
The phase II ELDERLY trial compared two first-line treatment options for older adults (age 70+) or frail patients with metastatic colorectal cancer who aren't eligible for full-dose chemotherapy combinations. Patients received either dose-reduced mFOLFOX7 (a chemotherapy doublet with oxaliplatin and fluorouracil) or aflibercept (an angiogenesis inhibitor that blocks blood vessel formation in tumors) combined with 5-FU. This non-comparative study evaluated whether these gentler regimens could provide benefit while minimizing toxicity in a vulnerable patient population.
What this means
If you're over 70 or have other health conditions that make standard chemotherapy too harsh, this trial provides evidence for treatment options specifically designed for your situation. Discuss with your oncologist whether a dose-reduced regimen might be appropriate for your care.